Ignite Creation Date:
2024-05-05 @ 8:00 PM
Last Modification Date:
2024-10-26 @ 9:57 AM
Study NCT ID:
NCT00782574
Status:
COMPLETED
Last Update Posted:
2023-12-21
First Post:
2008-10-29
Brief Title:
Phase I AZD2281Cisplatin in Advanced Solid Tumour Patients
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase I Open Label Multi Centre Study of AZD2281 Administered Orally in Combination With Cisplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumours
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03079687
Has Expanded Access, NCT# Status:
APPROVED_FOR_MARKETING
Acronym:
None
Brief Summary:
A Phase I study to assess the safety and tolerability of AZD2281 in combination with Cisplatin in patients with advanced Solid Tumours This is an open label-dose finding to establish the maximum tolerated dose of AZD2281 combined with Cisplatin in patients with advanced solid tumours Approximately 50 max 60 patients from 2 countries will be enrolled
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2008-000062-24 | EUDRACT_NUMBER | None | None |